Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (4.826)

1

Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2024

von Gebhart, G. | Keyaerts, M. | Guiot, T. | +23

2

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3) : a multicentre, single-arm, phase 2 study

enthalten in: The Lancet. Oncology | 2024

von van der Voort, A. | Louis, F. | van Ramshorst, M. | +52

3

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain) : a randomised, open-label, phase 2 trial

enthalten in: Lancet (London, England) | 2024

von Pérez-García, J. | Cortés, J. | Ruiz-Borrego, M. | +27

4

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01) : primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

enthalten in: The Lancet. Oncology | 2024

von Smit, E. | Felip, E. | Uprety, D. | +17

5

Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials

enthalten in: Critical reviews in oncology/hematology | 2024

von Ma, R. | Shi, Y. | Yan, R. | +3

6

Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer : Results from the drug rediscovery protocol (DRUP)

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Spiekman, I. | Zeverijn, L. | Geurts, B. | +15

7

Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma : a pooled analysis of two phase I studies

enthalten in: Japanese journal of clinical oncology | 2024

von Takahashi, S. | Bando, H. | Kinoshita, I. | +9

8

Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer : a real-world retrospective single-institutional study in China

enthalten in: World journal of surgical oncology | 2024

von Peng, D. | Li, J. | Qiu, J. | +1

9

Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?

enthalten in: JAMA oncology | 2024

von Sun, R. | Wei, L.

10

Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply

enthalten in: JAMA oncology | 2024

von Huober, J. | Thürlimann, B. | Dietrich, D.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[483]